Stocktoria

OnKure Therapeutics, Inc. OKUR

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-04-09

OnKure Therapeutics, Inc. financials (annual)

Revenue
$0 202020212022202320242025
Net income
-$19.5M -$39.8M -$52.0M -$35.3M -$52.7M -$59.5M 202020212022202320242025
Free cash flow
-$18.6M -$38.2M -$47.7M -$34.8M -$51.2M -$51.9M 202020212022202320242025

Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020
Revenue$0
R&D expense$48.3M$43.8M$32.1M$37.7M$28.2M$15.9M
Operating income-$63.0M-$54.4M-$36.9M-$53.8M-$39.8M-$19.6M
Income tax$0$0$0$0$0$0
Net income-$59.5M-$52.7M-$35.3M-$52.0M-$39.8M-$19.5M
EPS (diluted)$-4.40$-15.28$-124.41$-2.12$-2.19$-9.60
Operating cash flow-$51.8M-$51.1M-$34.5M-$47.4M-$38.0M-$18.5M
Free cash flow-$51.9M-$51.2M-$34.8M-$47.7M-$38.2M-$18.6M
Cash & equivalents$59.0M$110.8M$29.9M$19.9M$124.7M$53.6M
Total assets$62.1M$114.9M$35.7M$108.2M$154.0M$55.2M
Total liabilities$5.9M$11.1M$7.8M$8.2M$6.8M$4.6M
Shareholders' equity$56.2M$103.8M-$101.8M-$54.4M$147.2M-$42.1M

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.